Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $30.00 Average Price Target from Analysts

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have been given a consensus recommendation of “Buy” by the six brokerages that are covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $30.00.

A number of research firms recently weighed in on AVTX. Jefferies Financial Group began coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They issued a “buy” rating and a $23.00 price target on the stock. Stifel Nicolaus began coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They issued a “buy” rating and a $36.00 price target on the stock. HC Wainwright upgraded Avalo Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Monday, June 2nd. Piper Sandler began coverage on Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and issued a $18.00 price target on shares of Avalo Therapeutics in a research note on Thursday, March 20th.

Avalo Therapeutics Trading Up 3.6%

Shares of AVTX opened at $4.88 on Friday. The stock has a 50 day simple moving average of $4.48 and a 200 day simple moving average of $6.77. Avalo Therapeutics has a 52-week low of $3.39 and a 52-week high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Monday, May 12th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.18). As a group, equities research analysts anticipate that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

Institutional Trading of Avalo Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its stake in shares of Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after buying an additional 3,754 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Avalo Therapeutics in the first quarter valued at $80,000. Marshall Wace LLP bought a new stake in shares of Avalo Therapeutics in the fourth quarter valued at $114,000. Walleye Capital LLC bought a new stake in shares of Avalo Therapeutics in the fourth quarter valued at $145,000. Finally, Northern Trust Corp bought a new stake in shares of Avalo Therapeutics in the fourth quarter valued at $168,000. 87.06% of the stock is currently owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.